ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Marrone Bio Innovations Inc

Marrone Bio Innovations Inc (MBII)

0.7981
0.00
(0.00%)
At close: March 28 04:00PM
0.7981
0.00
( 0.00% )

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.7981
Bid
0.7803
Ask
0.80
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
0.7981
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

MBII Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
QLIQilian International Holding Group Ltd
$ 1.05
(52.20%)
2.85M
SBFMSunshine Biopharma Inc
$ 0.08
(32.23%)
26.19M
GRTXGalera Therapeutics Inc
$ 0.1731
(23.64%)
1.26M
MEDPMedpace Holdings Inc
$ 480.00
(18.77%)
1.41k
JSPRWJasper Therapeutics Inc
$ 0.2147
(17.97%)
600
XTKGX3 Holdings Company Ltd
$ 0.646
(-34.75%)
1.33M
VVOSVivos Therapeutics Inc
$ 3.60
(-25.47%)
86.98k
NVVENuvve Holding Corporation
$ 0.8625
(-21.59%)
138.49k
NDRAENDRA Life Sciences Inc
$ 0.4782
(-17.55%)
151.76k
XPONExpion360 Inc
$ 2.63
(-15.71%)
21.85k
SBFMSunshine Biopharma Inc
$ 0.08
(32.23%)
26.19M
CRKNCrown Electrokinetics Corporation
$ 0.0606
(1.17%)
7.37M
AAPLApple Inc
$ 171.28
(-0.12%)
3.57M
JAGXJaguar Health Inc
$ 0.0865
(-3.78%)
3.52M
GMDAGamida Cell Ltd
$ 0.0384
(6.37%)
3.39M

MBII Discussion

View Posts
Sirpeter Sirpeter 2 years ago
That's way high
👍️0
starkd748 starkd748 2 years ago
Not really weekly daily hrly rsi 90s too 100
👍️0
starkd748 starkd748 2 years ago
Maybe but the weekly daily rsi all high 90s
👍️0
Spicknspan Spicknspan 2 years ago
Nice move. With a little consolidation and higher basing, we may get somewhere for the long term
👍️0
Sirpeter Sirpeter 2 years ago
Damn me I sold too early...oh well
👍️0
Pickme2 Pickme2 2 years ago
My thumbs up emoji showed up as 2 question marks...oops
👍️0
Pickme2 Pickme2 2 years ago
?? great breakout...I was hoping my funds would have been in before this breakout so I could have bot 50k more...good luck
👍️0
Sirpeter Sirpeter 2 years ago
Looking for a breakout here
👍️0
Sirpeter Sirpeter 2 years ago
I would hang on to those shares...this is good one IMO
👍️0
tw0122 tw0122 2 years ago
Looks better on chart today only riding free shares now. Next week will show direction better
👍️0
Sirpeter Sirpeter 2 years ago
You still in this or am I here alone lol?
👍️0
Sirpeter Sirpeter 2 years ago
I'm in...looks ready to move back up
👍️0
tw0122 tw0122 2 years ago
Pro Farm Technologies, a subsidiary of Marrone Bio Innovations, Inc. (MBI) (NASDAQ: MBII) and Corteva Agriscience (NYSE: CTVA). Under the agreement, Corteva will be the exclusive European distributor for Kinsidro® Grow, a novel, foliar bionutrient that delivers key nutrients resulting in increased plant vigor.
“This agreement combines Marrone Bio’s leadership in the development of biological, sustainable crop solutions with Corteva’s global market leadership. Working with Corteva, we will bring our game-changing foliar technology to European growers who know and trust Corteva,” said Kevin Helash, chief executive officer of Marrone Bio Innovations.

Kinsidro Grow is a proprietary product developed by Pro Farm Technologies that optimizes nutrient conditions in plants resulting in improved plant health and crop quality. Through foliar application on crops during the vegetative growth stage, the bionutrient delivers better yields and more favorable returns on investment. Kinsidro Grow is also easy to use and compatible with a grower’s current agronomic practices.

“Corteva Agriscience continues to bring new and innovative solutions to market by offering natural-origin products that improve crop performance, resilience, and work complementarily with our conventional crop protection solutions,” said Susanne Wasson, President, Crop Protection Business Platform, Corteva Agriscience. “We’re excited to work with Marrone Bio to scale up and maximize sustainable options that help farmers meet changing environmental conditions while keeping their crops productive and healthy.”

This collaboration represents another step forward for Corteva’s expanding global biologicals portfolio, which is dedicated to developing biostimulants, biofertilizers, bionutrients, biocontrol and pheromone products with proven, predictable performance. Kinsidro Grow will provide value through enhanced crop vitality and enhancing yield potential and sustainability, in line with the Corteva Agriscience 2030 Sustainability Goals.

The multi-year agreement, which goes into immediate effect, applies to European row crops such as corn, soybeans, wheat, and cotton, and builds on the successful seed treatment agreement between both companies. In 2021, Pro Farm Technologies’ novel micronutrient seed treatment and growth promoter, Lumidapt®, was applied on more than 10 million Pioneer® corn, winter rapeseed, and sunflower seed hectares (25 million acres).

Marrone Bio’s Senior Vice-President of International Sales Matti Tianen added: “Corteva has a strong pulse on the needs of farmers throughout the region and is uniquely positioned to deliver our breakthrough fertilizer technology. We have spent a significant amount of time securing regulatory approvals and building technical sales knowledge, so we are ready to hit the ground running. We anticipate this partnership will be a material portion of our foliar fertilizer sales starting in the 2022 growing season.”
👍️0
tw0122 tw0122 2 years ago
Might want to revisit agro play so it’s a hot sector.
👍️0
Afterhoursearnings3 Afterhoursearnings3 2 years ago
This sure looks like bottom here doesn't it?
👍️0
Billydakidd Billydakidd 2 years ago
This company is about to take over agriculture and horticulture. To the moon !
👍️0
georgie18 georgie18 2 years ago
MBII...7691...Trying for the Upper Bollie Breakout here...imo...we shall see...been filling .69 to 90 range...:partying_face:
👍️0
Billydakidd Billydakidd 2 years ago
Cranking up
👍️0
georgie18 georgie18 2 years ago
MBII...7326...Psar flipped Bullish here...:partying_face:
👍️0
oxnous oxnous 2 years ago
Marrone Bio's Next-Generation Product for Environmentally Sustainable Pest Control Demonstrates Substantial Yield Gains in 2021 Field Trials

Estimated peak potential revenue for MBI-306 and its variants is $100 million


DAVIS, Calif., Dec. 08, 2021 — Field trials in 2021 for Marrone Bio Innovations’ (NASDAQ: MBII) next-generation product for environmentally sustainable control of yield-robbing pests in corn and soybeans demonstrated excellent efficacy with substantial yield gains at reduced application rates.

“MBI-306 continues to demonstrate the benefits that farmers and consumers desire in healthier foods grown with a lighter environmental footprint,” said Marrone Bio’s Chief Executive Officer Kevin Helash. “This second-generation product offers growers a more sustainable solution to controlling pests with better yields. Additionally, with a reduced application rate, MBI-306 will be even more competitive against leading synthetic standards in terms of efficacy, price and ease of use.” Helash added, “We anticipate MBI-306 and its variants will generate a peak potential revenue of $100 million, providing valuable return to our stakeholders as well.”

MBI-306 will offer corn growers a new alternative in treating for corn rootworm, a pest that accounts for more than $1 billion of crop damage annually1. When tested as a seed treatment to control corn rootworm larvae, MBI-306 improved corn yields by up to 23 bushels per acre, a 14% increase when compared with untreated seed. This bioinsecticide also outperformed the leading commercial standard, delivering a 4% yield advantage. These yield gains equate to an estimated return on investment of $131 per acre versus untreated seed and $41 per acre versus current commercial products.

Similar benefits were demonstrated against soybean cyst nematode, the leading pest in soybeans and contributor to more than $1 billion in crop damage2. As a seed treatment, MBI-306 increased soybean yields by 11 bushels an acre, a 19% improvement and $130 per acre in additional revenue versus untreated seed. This novel bionematicide also showed excellent control with 6% higher yields when compared with commonly used treatments, providing growers an additional $47 per acre in returns.

Marrone Bio is an international leader in sustainable bioprotection and plant health solutions, with 18 commercial products and 15 products in its research and development pipeline, including MBI-306. MBI-306 is a second-generation novel bioinsecticide/bionematicide built on the same proprietary microbe that serves as the active ingredient in the company’s Venerate® XC Bioinsecticide and Majestene® Bionematicide.

MBI-306 was recently submitted to the U.S. Environmental Protection Agency for approval and is anticipated to be commercially available for the 2023/2024 growing season. It has shown to be non-toxic to humans, wildlife, aquatic life, earthworms and pollinators.

MBI-306 also was tested in 2021 as a soil treatment, or in-furrow, for control of corn rootworm larvae, with an average yield advantage of more than 21 bushels per acre versus no treatment. Additional data on this and other 2021 field trial results can be found on the company’s blog https://marronebio.com/news/bio-bites/.

Sources

Utah State University Extension
University of Minnesota Extension
About Marrone Bio Innovations

Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented agricultural company leading the movement to environmentally sustainable farming practices through the discovery, development and sale of innovative biological products for crop protection, crop health and crop nutrition. Our portfolio of 18 products helps customers operate more sustainably while increasing their return on investment. The company’s commercial products are sold globally and supported by a robust portfolio of more than 500 issued and pending patents. Our end markets include row crops; fruits and vegetables; trees, nuts and vines; and greenhouse production. Marrone Bio’s research and development program uses proprietary technologies to isolate and screen naturally occurring microorganisms and plant extracts to create new, environmentally sound solutions in agriculture.

Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.
👍️0
georgie18 georgie18 2 years ago
Nice...
👍️0
IB_ IB_ 2 years ago
My order filled at .73 !!!!!!!!!!!!!!!!!!!!!!!!!!

I do not believe management will allow this to slip from the Nasdaq,

Best Regards,

IB_
👍️0
georgie18 georgie18 2 years ago
MBII...69...https://finance.yahoo.com/news/marrone-bio-next-generation-product-130000751.html
👍️0
georgie18 georgie18 2 years ago
MBII...Filled more @ 7199...range...:partying_face:
👍️0
georgie18 georgie18 2 years ago
MBII...9103...Added here on the Bullish Harami Cross Reversal Pattern to the Upside...

Bands are squeezing hard here...imo...we shall see...
👍️0
Floppyplants Floppyplants 2 years ago
Chart is starting to look good here...
👍️0
georgie18 georgie18 2 years ago
MBII...89...Looking for a Descending Channel Breakout...imo...we shall see...

Chart... https://schrts.co/qyzZDdXK ...
👍️0
luckydude777 luckydude777 2 years ago
This board could use a little life.
👍️0
musicman73 musicman73 3 years ago
This is about to take off here. GLTA!
👍️0
MinnieM MinnieM 4 years ago
Just noticed a recent change in CEO.

https://ih.advfn.com/stock-market/NASDAQ/marrone-bio-innovations-MBII/stock-news/82924367/current-report-filing-8-k
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements for Certain Officers.

On July 24, 2020, Marrone Bio Innovations, Inc. (the “Company”) issued a press release announcing that Kevin Helash, a Canadian citizen, received a visa and, as such, his appointment as Chief Executive Officer and a Class III director of the Company will take effect on August 3, 2020 (the “Employment Date”). As previously disclosed, the Company’s founder, Dr. Pamela Marrone, will remain as the Company’s Chief Executive Officer until the Employment Date, and, as previously announced, will thereafter continue to serve as a non-employee director of and consultant to the Company.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.








👍️0
conix conix 4 years ago
MBII Chart

👍️0
conix conix 5 years ago
Marrone Bio Innovations, Inc. Reports First-Quarter 2019 Financial Results


First-Quarter 2019 Revenues More Than Doubled to $8.7 Million, with Gross Margins of 57 Percent

DAVIS, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (MBII), an international leader in sustainable biopesticide and plant health solutions, has provided its financial results for the first quarter ended March 31, 2019.

Selected Operating and Financial Highlights

$ in millions Q1
2019 Q1
2018 % Increase
(Decrease)
Revenues $8.7 $4.3 102%
Gross Profit $5.0 $2.1 140%
Gross Margin 57.2% 48.1% +907 bps
Operating Expenses $8.6 $7.6 14%
Loss from Operations $(3.6) $(5.5) (34%)
Net Loss $(3.9) $(5.3) (25%)
Cash Used in Operations $7.7 $9.7 (22%)
Q1 2019 Financial Highlights

Revenues in the first quarter of 2019 improved by 102 percent to $8.7 million, compared with $4.3 million in the first quarter of 2018. The record quarterly sales were led by continued adoption of the Venerate family of products, both for foliar applications in vegetables and for soil- and seed-applied applications in row crops. Revenues also benefited from placement of Grandevo for in-season insect control in fruits and vegetables, as well as expanded market reach for Regalia to treat fungal diseases in trees, nuts and vines.
Gross margins reached 57.2 percent, benefiting from the higher net revenue and higher mix of the Venerate family of products and better manufacturing efficiencies.
The 14 percent increase in operating expenses reflected planned investments in the commercial organization and programs, and in field trials for key research and development projects, including a new proprietary biological herbicide. This increase was offset somewhat by a decrease in accounting and other professional consulting fees in the first quarter of 2019.
Net loss in the first quarter of 2019 was $3.9 million, or $(0.04) per share, compared with a net loss of $5.3 million, or $(0.07) per share, in the first quarter of 2018.
On a comparative basis, the first quarter of 2018 included a non-recurring net benefit of $1.8 million to other income related to the Company’s comprehensive financing and debt restructuring transactions. Additionally, the diluted weighted-average shares outstanding in the first quarter of 2019 were 110.7 million shares, compared with 74.6 million shares in the first quarter of 2018.
Cash used in operations for the first quarter of 2019 was $7.7 million, compared with cash used in operations of $9.7 million in the first quarter of 2018. The use of operating cash in the first quarter of 2019 reflected greater working capital requirements related to increased sales.
Management Commentary
“We have put a solid foundation in place – technically, commercially and financially – to drive revenue growth this year and set the stage for longer term growth. Our first-quarter results are a solid start to what we believe can be a transformative year for Marrone Bio,” said Dr. Pam Marrone, chief executive officer of Marrone Bio Innovations.

“As we broaden our customer outreach and distribution network, we expand our ability to sell our products for multiple uses within a given crop,” she added. “We have the technical flexibility to offer our products in combination with complementary traditional agricultural solutions or with other compatible biocontrol or biostimulant offerings, thus enhancing our revenue-generating capabilities.”

Operational Highlights

Regalia’s label in Brazil was expanded to control fungal and bacterial diseases on lettuces, carrots, papayas, mangoes, watermelons, sweet peppers and grapes.
Regalia Maxx biofungicide was approved for use on cannabis in Canada.
Distribution agreements for Regalia Maxx were reached with Plant Products, a full-service greenhouse supplier, for eastern and central Canada; and with TerraLink, a leading supplier of crop input products, for western Canada.
Venerate CG label was approved by the California Department of Pesticide Regulation (DPR) for use on cannabis.
👍️0
conix conix 5 years ago
Marrone Bio Innovations, Inc. Reports First-Quarter 2019 Financial Results


First-Quarter 2019 Revenues More Than Doubled to $8.7 Million, with Gross Margins of 57 Percent

DAVIS, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (MBII), an international leader in sustainable biopesticide and plant health solutions, has provided its financial results for the first quarter ended March 31, 2019.

Selected Operating and Financial Highlights

$ in millions Q1
2019 Q1
2018 % Increase
(Decrease)
Revenues $8.7 $4.3 102%
Gross Profit $5.0 $2.1 140%
Gross Margin 57.2% 48.1% +907 bps
Operating Expenses $8.6 $7.6 14%
Loss from Operations $(3.6) $(5.5) (34%)
Net Loss $(3.9) $(5.3) (25%)
Cash Used in Operations $7.7 $9.7 (22%)
Q1 2019 Financial Highlights

Revenues in the first quarter of 2019 improved by 102 percent to $8.7 million, compared with $4.3 million in the first quarter of 2018. The record quarterly sales were led by continued adoption of the Venerate family of products, both for foliar applications in vegetables and for soil- and seed-applied applications in row crops. Revenues also benefited from placement of Grandevo for in-season insect control in fruits and vegetables, as well as expanded market reach for Regalia to treat fungal diseases in trees, nuts and vines.
Gross margins reached 57.2 percent, benefiting from the higher net revenue and higher mix of the Venerate family of products and better manufacturing efficiencies.
The 14 percent increase in operating expenses reflected planned investments in the commercial organization and programs, and in field trials for key research and development projects, including a new proprietary biological herbicide. This increase was offset somewhat by a decrease in accounting and other professional consulting fees in the first quarter of 2019.
Net loss in the first quarter of 2019 was $3.9 million, or $(0.04) per share, compared with a net loss of $5.3 million, or $(0.07) per share, in the first quarter of 2018.
On a comparative basis, the first quarter of 2018 included a non-recurring net benefit of $1.8 million to other income related to the Company’s comprehensive financing and debt restructuring transactions. Additionally, the diluted weighted-average shares outstanding in the first quarter of 2019 were 110.7 million shares, compared with 74.6 million shares in the first quarter of 2018.
Cash used in operations for the first quarter of 2019 was $7.7 million, compared with cash used in operations of $9.7 million in the first quarter of 2018. The use of operating cash in the first quarter of 2019 reflected greater working capital requirements related to increased sales.
Management Commentary
“We have put a solid foundation in place – technically, commercially and financially – to drive revenue growth this year and set the stage for longer term growth. Our first-quarter results are a solid start to what we believe can be a transformative year for Marrone Bio,” said Dr. Pam Marrone, chief executive officer of Marrone Bio Innovations.

“As we broaden our customer outreach and distribution network, we expand our ability to sell our products for multiple uses within a given crop,” she added. “We have the technical flexibility to offer our products in combination with complementary traditional agricultural solutions or with other compatible biocontrol or biostimulant offerings, thus enhancing our revenue-generating capabilities.”

Operational Highlights

Regalia’s label in Brazil was expanded to control fungal and bacterial diseases on lettuces, carrots, papayas, mangoes, watermelons, sweet peppers and grapes.
Regalia Maxx biofungicide was approved for use on cannabis in Canada.
Distribution agreements for Regalia Maxx were reached with Plant Products, a full-service greenhouse supplier, for eastern and central Canada; and with TerraLink, a leading supplier of crop input products, for western Canada.
Venerate CG label was approved by the California Department of Pesticide Regulation (DPR) for use on cannabis.
👍️0
whytestocks whytestocks 5 years ago
News: $MBII Marrone Bio Innovations' Regalia® Maxx biofungicide approved for use on cannabis in Canada

DAVIS, Calif., April 10, 2019 (GLOBE NEWSWIRE) -- Marrone Bio Innovations Inc. (NASDAQ:MBII) (MBI), a leading developer of biological crop protection and plant health solutions, today announced that Regalia Maxx has received label approval from Canada’s Pest Management Regulatory A...

Find out more https://marketwirenews.com/news-releases/marrone-bio-innovations-regalia-xae-maxx-biofungicide-approved-for-use-on-cannabis-in-canada-7978250.html
👍️0
Schneidku40 Schneidku40 5 years ago
I thought we'd get more eyes with the news about acceptance in California and effectiveness on marijuana plants.
👍️0
damAcon1 damAcon1 5 years ago
Crickets! I guess no news is good news?
👍️0
whytestocks whytestocks 5 years ago
News: $MBII Marrone Bio Innovations CEO Pam Marrone to receive 'Sustie' award for her contributions to sustainable agriculture

PACIFIC GROVE, Calif., Jan. 25, 2019 (GLOBE NEWSWIRE) -- 39 th Annual EcoFarm Conference --  Dr. Pam Marrone , founder and CEO of Marrone Bio Innovations Inc. (NASDAQ: MBII), will be honored by the Ecological Farming Association tonight at the EcoFarm Awards Dinner Banquet. Sh...

Read the whole news https://marketwirenews.com/news-releases/marrone-bio-innovations-ceo-pam-marrone-to-receive-sustie-award-xa0-for-her-contributions-to-sustainable-agriculture-7551092.html
👍️0
Sbmlewis Sbmlewis 5 years ago
This place is dead.
👍️0
Kentuckyrose Kentuckyrose 6 years ago
Mbii has formed a solid cup and handle . it is now consolidating. Look for break out at 2.13
👍️0
Kentuckyrose Kentuckyrose 6 years ago
Mbii has formed a solid cup and handle and is consolidating . watch for the break out at 2.13
👍️0
InvestoGuy InvestoGuy 6 years ago
Marrone Bio Innovations to Host Virtual Roadshow Webinar on July 26th, 2018

https://investors.marronebio.com/news-releases/news-release-details/marrone-bio-innovations-host-virtual-roadshow-webinar-july-26th
👍️0
NYOptionsGuy NYOptionsGuy 6 years ago
Marrone Bio Innovations Unveils New Cannabis Crop Protection Products


SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/06/04/MBII-Marrone-Bio-Innovations-Unveils-New-Cannabis-Crop-Protection-Products


DAVIS, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, is pleased to announce the launch of REGALIA CG, GRANDEVO CG and VENERATE CG, a portfolio of products designed to control highly destructive pests and diseases, including powdery mildew, mites, thrips and aphids, during Cannabis production and home gardening.

REGALIA CG, GRANDEVO CG and VENERATE CG are multi-state-approved and extremely effective biological crop protection solutions for clean green cultivation, with the ability to generate increased yield and improved quality by reducing stresses from plant disease and insect and mite pests to the plant. When incorporated into an Integrated Pest Management (IPM) program, these products can serve as the fundamental difference for successful growers.



"GRANDEVO and VENERATE are a game changer when it comes to IPM programs,” said Kyle Stamback, Director of Cultivation at NorthWestGrown i502 and owner of Lean Cultivation LLC. “I have eliminated all other preventive sprays and only use Grandevo and Venerate. These products have kept my gardens clean and my beneficial bugs happy. I’ve seen great results against all types of malice bugs, from leaf eaters to root aphids."



“REGALIA has been considered the go-to product for powdery mildew control in the Cannabis industry,” said Kyle. “When using Regalia on a consistent schedule, I have documented increased vigor and stalk size. Due to the overall plant health, my yields have been remarkable. As a result of tank mixing Regalia and other great products offered by MBI, my plants have never been healthier and my IPM has never been simpler.”



REGALIA CG, GRANDEVO CG and VENERATE CG also help grow operations care for their employees and the environment. They are harvest flexible and worker-friendly with a four-hour re-entry interval, minimal personal protective equipment requirements and the ability to be used right before harvest without concern for synthetic chemical residues.



“Outreach to hundreds of growers and industry leaders helped MBI create a solution that addresses needs in information sharing, education and training, ultimately producing products they can use with confidence backed by science,” said Lisa Malabad, Cannabis Segment Lead at Marrone Bio Innovations. “We continue to work with state regulatory agencies to ensure each of our products is aligned with all requirements and guidelines, giving growers peace of mind.”



REGALIA CG and VENERATE CG are available in one quart and one-gallon sizes. Grandevo CG is available in one and four-pound packages.



About Marrone Bio Innovations



Bio With Bite.



Marrone Bio Innovations, Inc. (NASDAQ:MBII) strives to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for crop protection and plant health. MBI’s effective and environmentally responsible pest management solutions help customers operate more sustainably while uniquely improving plant health and increasing crop yields. MBI’s currently available commercial products are Regalia®, Grandevo®, Venerate®, Majestene®, Haven® StargusTM and AmplitudeTM, Zelto® and Zequanox®.



Marrone Bio Innovations is dedicated to pioneering smart biopesticide solutions that support a better tomorrow for both farmers, turf managers and consumers around the globe. For more information, please visit www.marronebio.com.



Marrone Bio Innovations Forward Looking Statements



This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding the potential of Regalia, Grandevo and Venerate CG and other MBI products in the US and Canada, market projections, including the potential benefits of Regalia CG. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company's control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.

👍️0
conix conix 6 years ago
To what do you account for this decline from over $3.00? I cannot see any negative news, except for the dilution, maybe.
👍️0
willlbone willlbone 6 years ago
Dilution at $1.65
👍️0
ClayTrader ClayTrader 6 years ago
* * $MBII Video Chart 04-06-18 * *

Link to Video - click here to watch the technical chart video

👍️0
shanak10 shanak10 6 years ago
Thanks for link.. another 13D filed
👍️0
NYOptionsGuy NYOptionsGuy 6 years ago
Analyst Rates Marrone Bio Innovations a 'Hold'

SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/02/08/MBII-Analyst-Rates-Marrone-Bio-Innovations-a-Hold

Jefferies' Laurence Alexander just announced a 'hold' rating on shares of Marrone Bio Innovations, Inc. (NASDAQ:MBII) alongside a price target of $1.15 per share. Based on three analysts we track that cover Marrone Bio, shares of MBII currently have an average price target of $2.33 per share.

With a last trade price of $1.18 for shares of Marrone Bio, this price target represents roughly 2.5% of potential downside.



Over the last few days, we've seen two large insider buy transactions on shares of MBII, sending bullish sentiment to existing and potential investors.
👍️0
shanak10 shanak10 6 years ago
check out latest filings.
👍️0
greenvestor2000 greenvestor2000 6 years ago
today 1.40 tomorrow 2.00 then cannrunning unstoppable
👍️0
greenvestor2000 greenvestor2000 6 years ago
@ the very beginning, volume rising
👍️0

Your Recent History

Delayed Upgrade Clock